Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $997000.0.

  • Anika Therapeutics' Interest & Investment Income rose 14556.65% to $997000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 921.66%. This contributed to the annual value of $2.3 million for FY2024, which is 108.13% up from last year.
  • Latest data reveals that Anika Therapeutics reported Interest & Investment Income of $997000.0 as of Q3 2025, which was up 14556.65% from $214000.0 recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Interest & Investment Income peaked at $997000.0 during Q3 2025, and registered a low of -$154000.0 during Q1 2022.
  • In the last 5 years, Anika Therapeutics' Interest & Investment Income had a median value of $415000.0 in 2025 and averaged $354789.5.
  • The largest annual percentage gain for Anika Therapeutics' Interest & Investment Income in the last 5 years was 100833.33% (2022), contrasted with its biggest fall of 25813.95% (2022).
  • Anika Therapeutics' Interest & Investment Income (Quarter) stood at -$47000.0 in 2021, then surged by 687.23% to $276000.0 in 2022, then soared by 109.06% to $577000.0 in 2023, then grew by 28.94% to $744000.0 in 2024, then surged by 34.01% to $997000.0 in 2025.
  • Its last three reported values are $997000.0 in Q3 2025, $214000.0 for Q2 2025, and $415000.0 during Q1 2025.